Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications
- PMID: 16943529
- DOI: 10.1200/JCO.2005.03.9909
Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications
Abstract
Purpose: Since febrile neutropenic patients were recognized to constitute a heterogeneous population, several models have been developed for predicting the risk of serious medical complications. The Multinational Association for Supportive Care in Cancer score and its derived clinical prediction rules have been validated, but thus far there were no data about its use for simplifying therapy in predicted low-risk patients.
Patients and methods: In a single institution, we followed all episodes of febrile neutropenia between January 1999 and November 2003. Those patients predicted at low risk for complications, who were not receiving antibacterials at fever onset and were eligible for treatment with oral antibiotics, were treated with ciprofloxacin and amoxicillin-clavulanate and were discharged if they were clinically stable or improving after an initial observation period. The primary end point of the study was the rate of resolution of the febrile neutropenic episode without complications, among these early discharged patients.
Results: Of 383 first febrile neutropenic episodes predicted at low risk of complication, 178 patients (33 men and 145 women, mainly with solid tumors) were treated orally; they constituted the basis of our analysis. Seventy-nine patients (44%) were discharged early (with a median time to discharge of 26 hours); no complications occurred among them but three patients had to be readmitted, resulting in a success rate of 96% (95% CI, 92% to 100%).
Conclusion: Our study shows that oral therapy followed by early discharge was feasible in a small but significant proportion of patients selected by a strategy combining predicted low risk and medical and nonmedical criteria.
Comment in
-
Outpatient oral antibiotics for febrile neutropenic cancer patients.J Clin Oncol. 2006 Dec 10;24(35):5614; author reply 5614-5. doi: 10.1200/JCO.2006.09.0571. J Clin Oncol. 2006. PMID: 17158551 No abstract available.
Similar articles
-
Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients.J Clin Oncol. 2005 Oct 20;23(30):7437-44. doi: 10.1200/JCO.2004.00.5264. J Clin Oncol. 2005. PMID: 16234511
-
Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia.Ann Hematol. 2007 Apr;86(4):263-70. doi: 10.1007/s00277-006-0248-4. Epub 2007 Jan 16. Ann Hematol. 2007. PMID: 17225113
-
Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients.Cancer. 1999 Jul 1;86(1):126-34. Cancer. 1999. PMID: 10391572 Clinical Trial.
-
Outpatient management of febrile neutropenia: time to revise the present treatment strategy.J Support Oncol. 2008 May-Jun;6(5):199-208. J Support Oncol. 2008. PMID: 18551855 Review.
-
Risk assessment and treatment of low-risk patients with febrile neutropenia.Clin Infect Dis. 2006 Feb 15;42(4):533-40. doi: 10.1086/499352. Epub 2006 Jan 6. Clin Infect Dis. 2006. PMID: 16421798 Review.
Cited by
-
A new prognostic model for chemotherapy-induced febrile neutropenia.Int J Clin Oncol. 2016 Feb;21(1):46-52. doi: 10.1007/s10147-015-0853-0. Epub 2015 Jun 7. Int J Clin Oncol. 2016. PMID: 26049405
-
H-ficolin serum concentration and susceptibility to fever and neutropenia in paediatric cancer patients.Clin Exp Immunol. 2009 Jul;157(1):83-9. doi: 10.1111/j.1365-2249.2009.03957.x. Clin Exp Immunol. 2009. PMID: 19659773 Free PMC article.
-
Clinical prediction models for febrile neutropenia and its outcomes: a systematic review.Support Care Cancer. 2025 Jun 4;33(7):537. doi: 10.1007/s00520-025-09562-y. Support Care Cancer. 2025. PMID: 40467900 Free PMC article.
-
Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients.Cochrane Database Syst Rev. 2013 Oct 9;2013(10):CD003992. doi: 10.1002/14651858.CD003992.pub3. Cochrane Database Syst Rev. 2013. PMID: 24105485 Free PMC article.
-
The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia.Support Care Cancer. 2013 Jun;21(6):1793-5. doi: 10.1007/s00520-013-1776-9. Epub 2013 Mar 24. Support Care Cancer. 2013. PMID: 23525960 No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical